Louvain-la-Neuve, Belgium, May 19 th , 2025 - In accordance with article 8:4 of the Royal Decree
of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam
Applications SA (“IBA”) hereby discloses information in relation to its share buyback program
announced on March 24 th , 2025.
Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA
ordinary shares on its behalf under the terms of a mandate with validity until December 31 st , 2025,
effective as from March 25 th , 2025, to cover the company’s obligations under long-term incentive
plans for management and certain members of its personnel.
In the framework of this share buyback program, IBA repurchased 26,500 IBA shares on Euronext
Brussels in the period from May 13 th , 2025 up to and including May 19 th , 2025, as follows:
The total number of shares purchased under this program therefore amounts to 582,849, following
this eighth week of execution. As a result, the current situation with respect to treasury shares
(held directly by IBA SA and indirectly through its subsidiary IBA Investments SRL) is the following:
About IBA
IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The
company is the leading supplier of equipment and services in the fields of proton therapy,
considered as the most advanced form of radiation therapy available today, as well as industrial
sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve,
Belgium, employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp)
meeting the highest standards of verified social and environmental performance.
IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and
Bloomberg IBAB.BB).
More information can be found at: https://www.iba-worldwide.com